Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database
This study indicated that the preventive effect of nirsevimab against RSV infection was maintained for up to 12 months following administration, whereas a preventive effect beyond 12 months was not observed. The results of this study need to be interpreted with caution owing to some important limitations.
Authors
- Taito Kitano (ORCID: https://orcid.org/0000-0003-0623-066X)
- Sayaka Yoshida (ORCID: https://orcid.org/0000-0002-1800-5104)
- Haruhisa Fukuda (ORCID: https://orcid.org/0000-0003-1120-1548)
- Shinya Tsuzuki (ORCID: https://orcid.org/0000-0001-5732-846X)
Institutions
- National Archives and Records Administration (US)
- Kyushu University (JP)
- Institute for Health Economics and Policy (JP)
- Nara Prefectural Institute of Public Health Research Center (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Journal of Infection
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1016/j.jinf.2025.106652
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development